Is ONC or PCVX more profitable?

BeOne Medicines has a net margin of 8.94% compared to Vaxcyte's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Vaxcyte N/A -32.51% -29.51%

Does the media favor ONC or PCVX?

In the previous week, Vaxcyte had 4 more articles in the media than BeOne Medicines. MarketBeat recorded 7 mentions for Vaxcyte and 3 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.32 beat Vaxcyte's score of 0.13 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PCVX or MRNA more profitable?

Vaxcyte has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Moderna -143.55% -26.64% -19.32%

Does the media refer more to PCVX or MRNA?

In the previous week, Moderna had 12 more articles in the media than Vaxcyte. MarketBeat recorded 19 mentions for Moderna and 7 mentions for Vaxcyte. Moderna's average media sentiment score of 0.72 beat Vaxcyte's score of 0.13 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 7 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is PCVX or ROIV more profitable?

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media refer more to PCVX or ROIV?

In the previous week, Vaxcyte had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 7 mentions for Vaxcyte and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.49 beat Vaxcyte's score of 0.13 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BNTX or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Vaxcyte N/A -32.51% -29.51%

Does the media prefer BNTX or PCVX?

In the previous week, Vaxcyte had 4 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for Vaxcyte and 3 mentions for BioNTech. BioNTech's average media sentiment score of 0.29 beat Vaxcyte's score of 0.13 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, INSM or PCVX?

Vaxcyte has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 41.65 -$1.28B -$5.75 N/A Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is INSM or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Vaxcyte's return on equity of -32.51% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Vaxcyte N/A -32.51% -29.51%

Does the media prefer INSM or PCVX?

In the previous week, Vaxcyte had 3 more articles in the media than Insmed. MarketBeat recorded 7 mentions for Vaxcyte and 4 mentions for Insmed. Insmed's average media sentiment score of 1.68 beat Vaxcyte's score of 0.13 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vaxcyte 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vaxcyte (PCVX) Competitors

$58.71 -1.96 (-3.23%)

Closing price 07/8/2026 04:00 PM Eastern

Extended Trading

$58.71 0.00 (0.00%)

As of 07/8/2026 06:17 PM Eastern

Compare

PCVX vs. ONC, MRNA, ROIV, BNTX, and INSM

Should you buy Vaxcyte stock or one of its competitors? MarketBeat compares Vaxcyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaxcyte include BeOne Medicines (ONC), Moderna (MRNA), Roivant Sciences (ROIV), BioNTech (BNTX), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Vaxcyte compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BeOne Medicines has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.20	$286.93M	$4.47	67.53
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

BeOne Medicines currently has a consensus price target of $391.38, indicating a potential upside of 29.65%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 46.48%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

BeOne Medicines has a net margin of 8.94% compared to Vaxcyte's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Vaxcyte	N/A	-32.51%	-29.51%

In the previous week, Vaxcyte had 4 more articles in the media than BeOne Medicines. MarketBeat recorded 7 mentions for Vaxcyte and 3 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.32 beat Vaxcyte's score of 0.13 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BeOne Medicines beats Vaxcyte on 12 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Moderna?

Vaxcyte (NASDAQ:PCVX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vaxcyte presently has a consensus price target of $86.00, suggesting a potential upside of 46.48%. Moderna has a consensus price target of $38.27, suggesting a potential downside of 48.15%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

In the previous week, Moderna had 12 more articles in the media than Vaxcyte. MarketBeat recorded 19 mentions for Moderna and 7 mentions for Vaxcyte. Moderna's average media sentiment score of 0.72 beat Vaxcyte's score of 0.13 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	7 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Moderna	-143.55%	-26.64%	-19.32%

Vaxcyte has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Moderna has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Vaxcyte has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Moderna	$1.94B	15.06	-$2.82B	-$8.15	N/A

Summary

Vaxcyte beats Moderna on 9 of the 15 factors compared between the two stocks.

How does Vaxcyte compare to Roivant Sciences?

Vaxcyte (NASDAQ:PCVX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Roivant Sciences has higher revenue and earnings than Vaxcyte. Roivant Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Roivant Sciences	$8.26M	3,142.67	-$299.77M	-$0.60	N/A

Vaxcyte has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Vaxcyte presently has a consensus price target of $86.00, suggesting a potential upside of 46.48%. Roivant Sciences has a consensus price target of $33.59, suggesting a potential downside of 6.92%. Given Vaxcyte's higher probable upside, equities research analysts clearly believe Vaxcyte is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Vaxcyte had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 7 mentions for Vaxcyte and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.49 beat Vaxcyte's score of 0.13 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Roivant Sciences beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does Vaxcyte compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Vaxcyte	N/A	-32.51%	-29.51%

BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

BioNTech presently has a consensus target price of $129.13, indicating a potential upside of 38.06%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 46.48%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Vaxcyte has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.29	-$1.29B	-$5.88	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

15.5% of BioNTech shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Vaxcyte had 4 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for Vaxcyte and 3 mentions for BioNTech. BioNTech's average media sentiment score of 0.29 beat Vaxcyte's score of 0.13 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioNTech beats Vaxcyte on 10 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Insmed?

Insmed (NASDAQ:INSM) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Vaxcyte had 3 more articles in the media than Insmed. MarketBeat recorded 7 mentions for Vaxcyte and 4 mentions for Insmed. Insmed's average media sentiment score of 1.68 beat Vaxcyte's score of 0.13 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vaxcyte	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	41.65	-$1.28B	-$5.75	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Vaxcyte's return on equity of -32.51% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Vaxcyte	N/A	-32.51%	-29.51%

Insmed presently has a consensus target price of $211.86, indicating a potential upside of 81.81%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 46.48%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Insmed has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

96.8% of Vaxcyte shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Vaxcyte beats Insmed on 9 of the 16 factors compared between the two stocks.

Get Vaxcyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCVX vs. The Competition

Export

Metric	Vaxcyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.76B	$3.80B	$6.99B	$12.46B
Dividend Yield	N/A	2.17%	2.67%	7.39%
P/E Ratio	-8.53	21.49	27.17	24.24
Price / Sales	N/A	328.43	534.05	96.53
Price / Cash	N/A	148.60	49.24	56.96
Price / Book	2.86	8.47	10.83	6.38
Net Income	-$766.63M	$23.73M	$3.56B	$331.19M
7 Day Performance	0.55%	0.14%	0.00%	-1.32%
1 Month Performance	25.23%	11.27%	5.29%	1.27%
1 Year Performance	64.09%	55.65%	30.32%	20.73%

Vaxcyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCVX Vaxcyte	2.2935 of 5 stars	$58.71 -3.2%	$86.00 +46.5%	+75.5%	$8.76B	N/A	N/A	160	Analyst Forecast Insider Trade
ONC BeOne Medicines	4.5839 of 5 stars	$309.46 +4.0%	$390.00 +26.0%	+23.5%	$32.66B	$5.34B	66.59	12,000	Analyst Downgrade Gap Up
MRNA Moderna	1.308 of 5 stars	$81.80 +2.6%	$37.13 -54.6%	+126.8%	$31.65B	$1.94B	N/A	4,700	Analyst Forecast Gap Down
ROIV Roivant Sciences	1.8148 of 5 stars	$35.39 +0.7%	$33.59 -5.1%	+232.3%	$25.27B	$8.26M	N/A	860
BNTX BioNTech	3.8033 of 5 stars	$93.93 -3.7%	$129.56 +37.9%	-16.2%	$24.67B	$3.25B	N/A	7,807	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCVX) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxcyte (PCVX) Competitors

PCVX vs. ONC, MRNA, ROIV, BNTX, and INSM

How does Vaxcyte compare to BeOne Medicines?

Summary

How does Vaxcyte compare to Moderna?

Summary

How does Vaxcyte compare to Roivant Sciences?

Summary

How does Vaxcyte compare to BioNTech?

Summary

How does Vaxcyte compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX vs. The Competition

Vaxcyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaxcyte (PCVX) Competitors

PCVX vs. ONC, MRNA, ROIV, BNTX, and INSM

How does Vaxcyte compare to BeOne Medicines?

Which has more volatility & risk, ONC or PCVX?

Do insiders and institutionals hold more shares of ONC or PCVX?

Which has preferable valuation & earnings, ONC or PCVX?

Do analysts prefer ONC or PCVX?

Is ONC or PCVX more profitable?

Does the media favor ONC or PCVX?

Summary

How does Vaxcyte compare to Moderna?

Do insiders & institutionals have more ownership in PCVX or MRNA?

Do analysts recommend PCVX or MRNA?

Does the media refer more to PCVX or MRNA?

Is PCVX or MRNA more profitable?

Which has more risk & volatility, PCVX or MRNA?

Which has higher earnings & valuation, PCVX or MRNA?

Summary

How does Vaxcyte compare to Roivant Sciences?

Is PCVX or ROIV more profitable?

Do insiders & institutionals have more ownership in PCVX or ROIV?

Which has stronger earnings and valuation, PCVX or ROIV?

Which has more volatility and risk, PCVX or ROIV?

Do analysts recommend PCVX or ROIV?

Does the media refer more to PCVX or ROIV?

Summary

How does Vaxcyte compare to BioNTech?

Is BNTX or PCVX more profitable?

Which has more volatility and risk, BNTX or PCVX?

Do analysts rate BNTX or PCVX?

Which has preferable earnings & valuation, BNTX or PCVX?

Do insiders and institutionals believe in BNTX or PCVX?

Does the media prefer BNTX or PCVX?

Summary

How does Vaxcyte compare to Insmed?

Does the media prefer INSM or PCVX?

Which has preferable valuation and earnings, INSM or PCVX?

Is INSM or PCVX more profitable?

Do analysts prefer INSM or PCVX?

Which has more volatility and risk, INSM or PCVX?

Do institutionals & insiders believe in INSM or PCVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX vs. The Competition

Vaxcyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools